Exclusive: AstraZeneca’s outgoing R&D chief Mene Pangalos reflects on a 14-year R&D turnaround and the industry's future
10 Aug 2023
Executive ChangePhase 3AcquisitionClinical Trial Failure
When AstraZeneca R&D executive Mene Pangalos joined the company in 2010, the UK drug giant was facing existential threats: shrinking sales, a meek pipeline and a takeover attempt by Pfizer.
Pangalos saw the biggest problem: AstraZeneca’s research wasn’t delivering. AstraZeneca had a 4% success rate in bringing drugs through Phase III, trailing a 6% industry average. He pushed a new focus on quality over quantity that, from 2012 to 2016, drove AstraZeneca’s success rate to 19% — even as the industry average fell to 4%.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.